Novian Health

Executive Summary

Novian Health is a Paris-based private company pioneering image-guided laser therapy as a minimally invasive alternative to surgery for tumor treatment, with an initial focus on breast cancer and non-cancerous breast tumors. Founded in 2018, the company has developed the Novilase laser procedure, which aims to benefit patients by reducing recovery time, scarring, and complications associated with traditional surgical excision. By leveraging advanced imaging to precisely target tumors, Novian Health is positioned to address a significant unmet need in women's oncology. The company operates at the intersection of digital health and AI/machine learning, though its core technology is a medical device. Despite limited public financial and operational data, Novian Health's niche focus on laser ablation for breast tumors aligns with the growing trend toward minimally invasive oncology procedures. The company's success will hinge on clinical evidence of safety and efficacy, regulatory approvals, and commercialization partnerships. As a private entity, it may be seeking Series A or B funding to advance its clinical pipeline and expand into other tumor types.

Upcoming Catalysts (preview)

• Q2 2027Publication of pivotal trial results for Novilase in breast tumors60% success
• Q4 2026CE marking or FDA clearance for Novilase system50% success
• Q3 2026Strategic partnership with a major medical device or pharmaceutical company for commercialization40% success